About
Small Molecules for Addiction Treatment
Areas of Focus
Categories
Small Molecule PharmaceuticalSoutheastern U.S.
Clinical Trials (17)
View allTotal Trials
17
As Lead Sponsor
13
As Collaborator
4
Total Enrollment
5,679
By Phase
PHASE2: 5PHASE3: 5NA: 1PHASE1: 1PHASE2/PHASE3: 1
By Status
COMPLETED: 10TERMINATED: 3RECRUITING: 2APPROVED_FOR_MARKETING: 1NO_LONGER_AVAILABLE: 1
Clinical Trials Pipeline15 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06564974Lead Sponsor
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy.
N/ARecruiting
250 participants
Started: Jul 31, 2024 · Completed: Nov 30, 2030
NCT03819660Lead Sponsor
Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
PHASE2Terminated
13 participants
Started: Mar 7, 2019 · Completed: Sep 13, 2021
NCT03781479Lead Sponsor
Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients
PHASE2Completed
13 participants
Started: Jan 21, 2019 · Completed: Jul 23, 2020
NCT03579966Lead Sponsor
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
PHASE3Terminated
63 participants
Started: Jun 11, 2018 · Completed: Aug 5, 2022
NCT03304054Lead Sponsor
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
PHASE3Completed
93 participants
Started: Apr 18, 2018 · Completed: Mar 15, 2020
Locations (1)
Headquarters
Coral Gables, FL, United States
Map
Loading map...